ipratropium (atrovent) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ipratropium (ipratropium bromide, ATROVENT® HFA) is a muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Ipratropium (ipratropium bromide, ATROVENT® HFA) is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca2+ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0983 - $19.4200

Australia

$6.2954 - $16.7000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( ipratropium (atrovent), albuterol (proventil) - other names: combivent respimat, duoneb )

Alternative names

3α-hydroxy-8-isopropyl-1αh,5αh-tropanium bromide (±)-tropate | 8-isopropylnoratropine methobromide | aer 001 | albuterol sulfate mixture with ipratropium bromide | atrovent | atrovent aerocaps | atrovent fte | atrovent hfa | atrovent udvs | bromure d'ipratropium | bromuro de ipratropio | (endo,syn)-(±)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide | ipratrop | ipratropii bromidum | ipratropium | ipratropiumbromid | ipratropium bromide | ipratropium bromide anhydrous | ipratropium bromide (anhydrous) | ipratropium bromide hydrate | ipratropium bromide monohydrate | ipratroprium | ipratrop steripoule | n-isopropylnoratropinium bromomethylate | respontin | rinatec | sch-1000-br- | sch-1000-br monohydrate | tropiovent

Organizations (107)

Research & Development (86)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (5)


 

Bronchial Spasm

Bronchitis, Chronic

Common Cold

Emphysema

Pulmonary Disease, Chronic Obstructive

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Airway Management (Phase 4)

Asthma (Phase 4)

Asthma, Exercise-Induced (Phase 4)

Bronchitis (Phase 4)

Cold Temperature (Phase 4)

Depression (Early Phase 1)

Dysautonomia, Familial (Phase 3)

Healthy Volunteers (Phase 1)

Laryngeal Diseases (Phase 2)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Parkinson Disease (Phase 2)

Pulmonary Arterial Hypertension (Phase 3)

Pulmonary Disease, Chronic Obstructive ()

Sialorrhea (Phase 2)

Status Asthmaticus (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 109
  • # of Trial Organizations: 86

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue